Biopharma SHAKTI: ₹10,000 Crore Budget 2026-27 Push
Why in the news
Finance Minister Nirmala Sitharaman’s Union Budget 2026-27 set aside ₹10,000 crore for Biopharma SHAKTI. The aim is to make India a global centre for biopharmaceutical manufacturing and innovation, reducing reliance on imported high-value biologics.
Key facts
- Biopharma SHAKTI = Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation.
- Outlay and duration: ₹10,000 crore over 5 years, built around long-gestation capacity creation, not short-term subsidies.
- Disease focus: cancer, diabetes, autoimmune disorders and other lifestyle-linked non-communicable diseases.
- NIPERs: 3 new institutes and upgrade of 7 existing ones for bioprocess engineering, regulatory science and clinical research training.
- Clinical trials: a network of 1,000+ accredited India Clinical Trials sites.
- CDSCO: strengthened with a dedicated scientific review cadre, aiming at global-standard approval timelines.
- 3 Chemical Parks on a cluster-based, plug-and-play model.
Components at a glance
| Area | Measure |
|---|---|
| Education and research | 3 new + 7 upgraded NIPERs |
| Trials | 1,000+ accredited sites |
| Regulation | CDSCO scientific review cadre |
| Industrial base | 3 Chemical Parks |
| Agri-biotech | Bharat-VISTAAR multilingual AI platform with ICAR knowledge |
| Clean energy | Biogas value excluded from Central Excise on biogas-blended CNG |
| Traditional medicine | Upgrade of WHO Global Traditional Medicine Centre, Jamnagar |
Background
- India leads in small-molecule generics but trails in biologic innovation and complex manufacturing.
- Biologics take a large and rising share of global drug spending; biosimilars give cheaper alternatives, export scope and health security.
- Chemical parks are meant to cut dependence on imported intermediates, ensure environmental compliance and lower input costs.
- Bharat-VISTAAR links ICAR knowledge with AI advisory to support medicinal plants, bio-inputs and farm-to-lab linkages.
- AYUSH push: upgrading the Jamnagar centre for scientific validation of traditional medicine and scaling quality Ayurvedic exports, benefiting medicinal-plant farmers, youth and MSMEs.
Significance and challenges
- Health security through lower dependence on imported biologics and wider access to advanced therapies.
- High-value manufacturing, exports and jobs in R&D, trials, manufacturing and regulation.
- Challenge: heavy capital and skill needs, regulatory agility without compromising safety, and close industry-academia ties.
Exam angle
- Expansion: Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation.
- Numbers to recall: ₹10,000 crore, 5 years, 3 + 7 NIPERs, 1,000+ trial sites, 3 Chemical Parks.
- Related terms: CDSCO, Bharat-VISTAAR, ICAR, biosimilars, anaerobic digestion.